🇺🇸 FDA
Pipeline program

Darovasertib

NADOM

Phase 2 small_molecule completed

Quick answer

Darovasertib for Ocular Melanoma is a Phase 2 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Ocular Melanoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials